Mydecine Innovations Group is a life sciences company dedicated to the development and commercialization of adaptive pathway medicines, natural health products and digital health solutions.
Currently Mydecine Innovations Group encompasses three companies, each with its own unique vertical focus and core strengths that position it to be a market leader. Collectively these companies also act as an integrated entity that is greater than the sum of its parts, both in output and impact.
Stock Performance
Mydecine News 66 articles
- Mydecine Innovations Group Provides Update on Annual Financial Statements
- Mydecine Innovations Group Announces Strategic Board and Management Changes
- Mydecine Innovations Group Inc – Annual and Q1 Financial Statements
- Mydecine Innovations Group Inc Provides Bi-Weekly Status Report
- Mydecine Receives Management Cease Trade Order
- Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds
- Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound
- Mydecine Announces Update Regarding the Special Access Program
- Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements
- Mydecine Provides Q4 2023 Business Update
- Mydecine Innovations Group gearing up for human trials after completing Aquis listing
- Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK and First Day of Dealings
- Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO
- Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date
- Mydecine Innovations Announces Closing of Prospectus Supplement Financing
- Mydecine Innovations Group Files Prospectus Supplement
- Mydecine Announces Conditional Approval of CSE Listing
- Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2023
- Mydecine Innovations Group Provides Corporate Update
- Mydecine Reports its Special Meeting Results
- Mydecine Innovations Group Announces Closing Under Share Subscription Agreement
- Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement
- Mydecine Announces Debt Settlements
- Mydecine Innovations Group Announces Closing Under Share Subscription Agreement
- Mydecine Innovation Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement
- Mydecine Innovations Group Announces Closing Under Share Subscription Agreement
- Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement
- Mydecine Innovations Group Announces Closing Under Share Subscription Agreement and Welcomes New CFO
- Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement
- VIDEO: Interview with Josh Bartch, CEO of Mydecine Innovations Group
- Mydecine Repositions For A Successful Future
- PanGenomic Health Inc Signs a Non-binding Letter of Intent for the Acquisition of Mindleap Health Inc.
- Mydecine Innovations Group Announces Common Share Subscription Agreement
- Psychedelic Sector News – Weekly Extractions: August 24, 2022
- Mydecine Innovations Group Announces Private Placement; Interim Changes to Management and Board of Directors
- Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs
- U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation
- Mydecine Announces Closing of Overnight Marketed Public Offering of Units
- Mydecine Innovations Group Announces Closing Under Share Subscription Agreement
- Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules
Showing the 40 most recent of 66 articles.